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ing responsible for nosocomial infec-
tion. Items used during the patient’s 
ocular surgery were conﬁ  rmed to be 
disposable and nonreused.
Topical drops of corticosteroids 
commonly applied during cataract 
surgery for intraocular lens implanta-
tion penetrate ocular structures. An 
alternative hypothesis is that corticos-
teroids applied during ocular surgery 
reactivate a latent ocular infection. 
Our review indicated that 13 of 19 
patients with documented T. whipplei 
uveitis had received topical or system-
ic corticosteroids before the diagnosis 
(Table) (7). Worsening of Whipple 
disease has been reported in patients 
receiving corticoid therapy for arthral-
gia (10). We speculate that our patient 
had an asymptomatic ocular infection 
before surgery.
This case shows that ocular sur-
gery and use of topical corticosteroids 
that penetrate ocular structures could 
reactivate a latent T. whipplei ocular 
infection. We suggest that patients 
with postoperative panendophthalmi-
tis be tested for T. whipplei by PCR.
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Klebsiella 
pneumoniae 
Carbapenemase, 
Canada
To the Editor: Carbapenems are 
used to treat life-threatening infections 
caused by extremely drug-resistant 
gram-negative pathogens; these drugs 
represent the last line of defense in the 
antimicrobial drug armamentarium 
against serious or invasive infection 
(1). The rapid global spread of Kleb-
siella pneumoniae that produces K. 
pneumoniae carbapenemase (KPC), 
especially in the northeastern United 
States (e.g., New York state), is of ma-
jor concern (2,3). KPC β-lactamases 
belong to the family of serine car-
bapenemases and are usually found 
in  K. pneumoniae and Escherichia 
coli. KPC hydrolyzes β-lactam agents, 
thereby reducing their action. KPC 
activity has been reported, albeit less 
frequently, in other family Enterobac-
teriaceae ( K. oxytoca,  Enterobacter 
spp., Salmonella spp., Citrobacter fre-
undii, and Serratia spp.) as well as in 
Pseudomonas aeruginosa (1).
The blaKPC genes have been identi-
ﬁ  ed on conjugative plasmids and pose 
an infection control problem because 
plasmids could theoretically be trans-
mitted from one species to another (4). 
The few therapeutic options for treat-
ing infections caused by organisms 
containing these β-lactamases are 
aminoglycosides, glycylcyclines, pol-
ymyxins, or combinations (1). A ma-
jor concern is that routine susceptibil-
ity testing methods based on existing 
breakpoints can falsely identify KPC 
producers as susceptible to carbapen-
ems. Such results pose the potential 
risk for increased illness and death, 
longer hospital stays, and nosocomial 
spread of infection.
In 2008, the Public Health Labo-
ratory in Toronto received clinical iso-
lates of K. pneumoniae from urine and 
sputum of 1 patient. The hospital labo-
ratory had forwarded the isolates to the 
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Public Health Laboratory because they 
were possible KPC producers. The pa-
tient was a 73-year-old man with a his-
tory of emphysema and hypertension, 
seen at a tertiary care hospital in the 
Toronto area, 80 miles from the New 
York state border, for a laparoscopic 
right radical nephrectomy because of 
hypernephroma. He had no risk fac-
tors for acquisition of KPC producers, 
e.g., travel to the United States or prior 
carbapenem exposure.
Susceptibility testing of K. pneu-
moniae was performed by the agar di-
lution method, using breakpoints set by 
the Clinical and Laboratory Standards 
Institute (5,6). The sputum isolate 
(7315) was susceptible to meropenem 
(MIC 4 μg/mL), and the urine isolate 
(7184) was intermediately susceptible 
(MIC 8 μg/mL). The K. pneumoniae 
isolates were screened for extended-
spectrum  β-lactamases (ESBLs) and 
AmpC production according to On-
tario guidelines (7).
Brieﬂ  y, to screen for ESBL enzy-
matic activity, a double-disk diffusion 
method was used: a clavulanic acid–
containing disk was placed adjacent 
to a disk containing one of several ce-
phalosporins such as ceftazidime and 
cefotaxime. Enhanced killing of the 
organism in the area between the drug 
with and without clavulanate indicates 
ESBL. Cefoxitin resistance (zone <17 
mm) indicates AmpC-like β-lactamase 
activity. In addition, testing for ESBL/
AmpC was performed according to 
Clinical and Laboratory Standards 
Institute guidelines (6). When the 
screening result for ESBL or AmpC 
is positive, the clinical laboratory is-
sues a warning that no β-lactam ex-
cept carbapenems can effectively treat 
this infection. The Table summarizes 
results of initial susceptibility testing 
and supplementary laboratory testing 
for KPC.
The initial result was consistent 
with a possible AmpC/ESBL producer 
for the sputum and urine isolates (6,7). 
However, because the patient respond-
ed poorly to empiric vancomycin and 
imipenem therapy and because of the 
elevated MIC to meropenem for iso-
late 7184, further laboratory testing 
was conducted to rule out the possibil-
ity of carbapenemase activity.
The modiﬁ   ed Hodge test is a 
phenotypic test proposed to conﬁ  rm 
the presence of carbapenemase ac-
tivity such as KPC in K. pneumo-
niae and E. coli (8). Universal prim-
ers for blaKPC family, Uni-KPC-F 
(5′-ATGTCACTGTATCGCCGTCT-
3′) and -R (5′-TTACTGCCCGTTGA
CGCCC-3′), were used for the entire 
882-bp coding sequence. Amplicons 
were bidirectionally sequenced by us-
ing the BigDye Terminators method and 
a 3130xl Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA) 
and primers Uni-KPC-F and -R. Mul-
tiple nucleotide and protein sequence 
alignments were performed with the 
ClustalW2 software (www.ebi.ac.uk/
Tools/clustalw2/index.html). To aid the 
clinician, an Etest method was used to 
measure the MIC of this KPC-produc-
ing K. pneumoniae isolate to colistin 
(0.5  μg/mL) and tigecycline (2.0 μg/
mL). However, before this information 
could be used, the patient had died of 
respiratory failure, presumably caused 
by  K. pneumoniae. Infection control 
measures and laboratory screening 
were undertaken in the hospital to limit 
transmission to other patients.
This report shows that KPC-pro-
ducing organisms such as K. pneumo-
niae may pose a major risk for clinical 
disease and a challenge for infection 
control if they were to spread to other 
hospitals in Canada. Current testing al-
gorithms focus on ESBL- and AmpC-
producing gram-negative bacteria, 
which may not detect KPC-producer 
strains. We suggest that reference lab-
oratories validate a screening method 
coupled with conﬁ  rmatory phenotypic 
assay for carbapenemase activity for 
suspected organisms, especially K. 
pneumoniae and E. coli. Our in-house 
validation studies conﬁ  rm that use of 
the ertapenem disk followed by the 
modiﬁ  ed Hodge test to conﬁ  rm car-
bapenemase activity may be effective 
(D.R. Pillai et al., unpub. data). Public 
health ofﬁ  cials should be aware that 
this report further expands the interna-
tional distribution of KPC-producing 
K. pneumoniae.
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Table. Results of initial susceptibility and supplementary testing for Klebsiella pneumoniae carbapenemase in urine and sputum 
samples from 73-year-old man, Canada* 
MIC, μg/mL†  Disk diffusion results, mm 
Isolate  AMP  FOX  CIP  GEN  CTRX MEM  FOX  CAZ  CAC  CTX  CTC  Initial report‡ 
Final 
report§ 
7184 >16  >16  >2  8 >32 8  16  0  14 13 15  AmpC/ESBL  KPC 
7315 >16  >16  >2  8 >32 4  0  0  8  13 15  AmpC/ESBL  KPC 
*AMP, ampicillin; FOX, cefoxitin; CIP, ciprofloxacin; GEN, gentamicin; CTRX, ceftriaxone; MEM, meropenem; CAZ, ceftazidime; CAC, ceftazidime-clavulanic 
acid; CTX, cefotaxime; CTC, cefotaxime-clavulanic acid; ESBL, extended-spectrum ȕ-lactamase; KPC, Klebsiella pneumoniae carbapenemase. 
†MIC values for clinical isolates 7184 (urine) and 7315 (sputum) were obtained by using agar macrodilution. 
‡Initial screening for ESBL or AmpC ȕ-lactamase activity, performed by Kirby Bauer disk diffusion according to Clinical Laboratory Standards Institute 
guidelines (6,7), suggested ESBL or AmpC ȕ-lactamase activity. 
§Supplementary modified Hodge test; PCR (specific for blaKPC family), and DNA sequencing confirmed the presence of KPC activity due to blaKPC-2. LETTERS
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Cryptosporidium sp. 
Rabbit Genotype, 
a Newly Identiﬁ  ed 
Human Pathogen 
To the Editor: Most human cases 
of cryptosporidiosis are caused by 
Cryptosporidium parvum or C. homi-
nis, but pathogenicity of some unusual 
Cryptosporidium species/genotypes is 
uncertain (1). In July 2008, an outbreak 
caused by Cryptosporidium sp. rabbit 
genotype was linked to consumption 
of tap water in Northamptonshire, 
England (2). On June 23 and 24, Cryp-
tosporidium oocysts were detected by 
operational monitoring of treated wa-
ter at a surface water treatment works. 
A precautionary boil-water notice was 
implemented on June 25.
Enhanced surveillance for cases 
was established by the health protec-
tion team on June 25 in the affected 
area. Eight single-well immunoﬂ  uo-
rescent microscopy slides, on which 
oocysts were detected by water com-
pany sampling of the distribution sys-
tem, were sent to the UK Cryptospo-
ridium Reference Unit, Swansea, for 
typing. Slides contained 49–259 oo-
cysts. Coverslips were removed after 
softening the seal with nail polish re-
mover. Fixed material was resuspend-
ed from the slides by thorough scrap-
ing of the entire well with a pipette 
tip twice with 50 μL lysis buffer AL 
(QIAGEN, Crawley, UK) and twice 
with 50 μL reverse osmosis water to a 
ﬁ  nal volume of 200 μL. Oocysts were 
disrupted in 3 dry ice/methanol freeze-
thaw cycles, and DNA was extracted 
by using the QIAamp DNA Mini Kit 
(QIAGEN), which involved digestion 
with proteinase K in lysis buffer AL at 
56°C for 30 min, puriﬁ  cation in a spin 
column, elution in 50 μL buffer AE, 
and storage at –20°C (3).
Cryptosporidium oocysts were 
also detected by direct immunoﬂ  uo-
rescent antibody test (IFAT) (Crypto-
Cel; TCS Biosciences, Buckingham, 
UK) in large bowel contents from 
a rabbit carcass removed by the wa-
ter company from a tank at the water 
treatment works. Oocysts were sepa-
rated from fecal debris by ﬂ  otation, 
resuspended in reverse osmosis water 
(4), and processed as above.
Cryptosporidium species were 
identiﬁ  ed by bidirectional sequencing 
of PCR products generated by nested 
PCR for the small subunit (SSU) 
rRNA gene (5) from 4 DNA aliquots 
of each sample. SSU rDNA sequenc-
es from 7 water samples, containing 
49–197 oocysts, and the rabbit isolate 
were homologous with isolates from 
rabbits in the People’s Republic of 
China (6) and the Czech Republic (7) 
(GenBank accession nos. AY120901 
and AY273771, respectively) (online 
Appendix Table, available from www.
cdc.gov/EID/content/15/5/829-appT.
htm). One sample from 1,391 L of wa-
ter contained 259 oocysts but was not 
ampliﬁ  ed. Other cryptosporidia were 
not identiﬁ  ed.
Human stool samples from 34 lo-
cal laboratory-identiﬁ  ed cases of cryp-
tosporidiosis in the affected area were 
sent to the UK Cryptosporidium Ref-
erence Unit for typing. To differentiate 
rabbit genotype from C. hominis (1), 
enhanced typing by SSU rRNA nested 
PCR–restriction fragment length poly-
morphism analysis with SspI and VspI 
(1,5) was used for all isolates submit-
ted to the UK Cryptosporidium Ref-
erence Unit during July and August. 
Samples from 23 cases (22 primary 
and 1 secondary) with rabbit genotype 
proﬁ  les were identiﬁ  ed by visualiza-
tion of 472-, 267-, and 109-bp bands 
generated by digestion with SspI (1). 
All case-patients lived in the area af-
fected by the water supply incident 
and had onset dates consistent with 
exposure by drinking water consump-
tion or by person-to-person spread. 
All 23 samples were homologous to 
AY120901 and AY273771 (online Ap-
pendix Table). Of the other 11 samples, 
6 were not conﬁ  rmed by IFAT or PCR, 
2 were C. hominis, 1 was C. parvum, 
and 2 were not typeable.
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